Clostridium difficile outbreak

Our Solutions

Whether hospitals are looking to generate additional revenues by treating more patients each year, or looking to make financial savings from already stretched budgets, addressing C. difficile infection needs to be a key part of a hospital’s infection control strategy.

The effective eradication of C. difficile is difficult to achieve even when using disinfectants that are active against C. difficile spores. This is due to the need for adequate distribution and contact time of the disinfectant in complex hospital environments. Additionally, sensitive medical equipment is not compatible with many liquid cleaning agents and bleach (sodium hypochlorite) is poorly tolerated by patients, visitors and healthcare workers (HCWs).

Generating value through the use of Bioquell bio-decontamination

Bioquell’s hydrogen peroxide vapour (HPV) technology is an effective, automated and repeatable surface bio-decontamination system. It is designed to achieve total eradication of C. difficile from the environment, verified by inactivation of 6-log Geobacillus stearothermophilus biological indicators, the same method used to validate steam sterilisers/autoclaves. Critically, it does not rely on the operator to ensure the distribution and contact time required to eradicate C. difficile spores.

Bioquell provides the only room/area bio-decontamination technology on the market with a proven track record in reducing the incidence of CDI in both endemic and epidemic settings. One American study has shown that the hospital-wide use of Bioquell HPV technology to bio-decontaminate a room used to care for C. difficile patients resulted in a statistically significant 53% reduction in the incidence of CDI1 and another US study showed a 42% reduction. Furthermore, Bioquell’s technology has been used in UK hospitals to control outbreaks of C. difficile. Several UK hospitals use Bioquell daily for the bio-decontamination of rooms used to care for patients with C. difficile. Reducing C. difficile acquisition rates reduces the direct costs of CDI and provides further benefits in terms of increased patient turnover.

Make an enquiry

Benefits

• Eradication of C. difficile from the hospital environment - Bioquell's technology has been scientifically proven to reduce C. difficile infection rates
   
• Poor clinical outcomes, increased length of stay and higher patient treatment costs are avoided
   
• There is no reliance on the operator to ensure distribution and contact time to eradicate the C. difficile spores
   
• Full reporting available to assist with hospitals management, as well as to support regulatory requirements
   
• World wide experience - Bioquell has successfully bio-decontaminated over 40,000 rooms at risk of C. difficile contamination worldwide
   

Make an enquiry

FAQs

Make an enquiry